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247 Clinical value of cough swab samples, versus induced sputum
samples in children with cystic ﬁbrosis
C. Lilos1, E. Hatziagorou1, F. Kirvassilis1, V. Avramidou1, M. Ioannou1,
D. Soﬁanou2, P. Savopoulou2, J. Tsanakas1. 1Paediatric Pulmonology Unit,
Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece;
2Dept of Microbiology, Hippokration Hospital, Thessaloniki, Greece
Introduction: Early detection and treatment of lower respiratory tract infections are
essential in the management of patients with cystic ﬁbrosis (CF), who often have
signs or symptoms of respiratory infection without any pathogens from sputum or
cough swab specimens.
Aim: To assess the efﬁcacy and clinical value of obtaining sputum and oropharyn-
geal cough swab samples following induction with hypertonic saline (HS) in this
group of patients.
Methods: Thirty-one outpatients with CF, mean age 6.2 years (range,
0.2−13.9 years), were recruited over a 6-month period. Nebulized salbutamol was
administered, followed by 7.5% HS for 15 minutes. Sputum was obtained before
and after HS induction. If the patient was not able to expectorate, oropharyngeal
cough swab was taken instead.
Results: Pathogens were isolated from HS-induced samples, but not from their
pre-induced specimens in four cases (12.9%). In three cases (9.6%) the treatment
was modiﬁed according to the positive culture of pathogens only from HS-induced
samples. The procedure was tolerated in all of the patients.
Conclusions: Cultures from induced sputum specimens provide additional microbi-
ological information, which is of clinical value and may lead to changes in patient
management.
248 Are exhaled and nasal NO measurements useful in CF adult
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Introduction: Exhaled NO (FeNO) is elevated in inﬂammatory lung diseases such
as asthma, but it has been found low to normal in CF. In addition nasal NO
(nNO) is also thought to be decreased in CF. However, studies have provided
controversed data, and the effect of low FEV1, of exacerbations and of colonization
with Pseudomonas aeruginosa (Pa) on NO values are not clear.
Methods: we measured FeNO (316) and nNO (225) in 32 adults CF patients
followed at our clinic over a 2.5 years period. Measurements were performed with
a NIOX® analyzer. Mean age of the patients was 29.4±8 years and mean FEV1
was 66.5±3.7%. 23/32 patients were colonized with Pa.
Results: median FeNO value was 7.5 ppb in patients colonized with Pa vs. 9.2 ppb
in patients not colonized (not signiﬁcant) [normal 5−25]. Median nNO was 417
ppb in patients colonized with Pa vs. 306 ppb in patients not colonized (p< 0.001)
[normal 827±320 ppb]. 69% of FeNO values but only 26% of nNO values were in
the normal range. No correlation was found between FeNO and nNO and FEV1, but
a signiﬁcant correlation was present between FeNO and nNO levels (p< 0.0001).
Three patients had FeNO values mostly over 30 ppb (up to 82 ppb) and presented
mainly with a pancreatic form of the disease. Finally, 1 patient had a FeNO increase
from 8 to 35 ppb because of asthma.
Conclusions: a low value of FeNO may suggest the diagnosis of CF but normal
values are common. FeNO is not associated with Pa colonization or FEV1 decrease.
In contrast, colonization with Pa is correlated with higher nNO levels. Interestingly,
a high FeNO value may be suggestive of concomitant asthma or of a predominantly
pancreatic form of CF. FeNO and nNO measurements might be useful in CF but
more data are needed to clarify their interest in clinical practice.
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Background: Several measurements are used to assess the response to treatment
of acute pulmonary exacerbations (PEx) in CF. However, the best measurement of
outcome of treatment has not been agreed upon. The magnitude of change of each
parameter at the end of treatment has also not been prospectively evaluated.
Patients and Methods: A symptom score (SS) system was developed, consisting
of the sum of scores of the 4 commonest respiratory CF symptoms: cough, sputum,
breathlessness, fatigue. Each symptom was scored from 1−4, 4 being the worst.
50 adult patients (18 male, mean age 25.2 y) with a diagnosed PEx deemed to start
antibiotic treatment underwent expiratory and inspiratory spirometry and impulse
oscillometry (IOS) at the start, days 7 and 14 of treatment. SS was also calculated.
The best spirometry values in the year prior to the study were recorded for
comparison.
Results: Compared to the best values in the year prior to the study, PEF was the
measurement that deteriorated the most at the start of a PEx. Comparing values at
the start and end of a PEx, SS improved in 38/50 (76%) and PEF, FEV1 and FVC
improved in 31/50 (62%).
The degree of improvement was greatest in SS (median change of 3 points),
followed by PEF. The mean (SD) improvements of spirometry values in percentage
predicted were: PEF 9.5% (15.5), FEV1 4.3% (8.0), FVC 5.9% (10.41). The major
improvements were seen already on day 7.
Inspiratory values changed to a smaller extent compared to expiratory components.
None of the IOS components changed signiﬁcantly from start to end of a PEx.
Conclusions: On day 14 of treatment, changes were greatest in SS and PEF.
The degree of changes in spirometry were surprisingly small. IOS and inspiratory
parameters were not sensitive to change.
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In CF patients, the efﬁcacy of antiinﬂammatory and antiinfectious treatment has to
be controlled. For this purpose stable substances are needed that can be collected
non-invasively and repeatedly. We investigated, if lactate can serve as a marker
substance. In 25 adult CF patients, sputum lactate concentrations were determined
spectrophotometrically and gaschromatographically and correlated with lung func-
tion values. In seven additional CF patients with exacerbations, lactate was measured
before and after antibiotic treatment. In puriﬁed neutrophils and in suspensions of
Pseudomonas aeruginosa, Staphylococcus aureus and Burkholderia cenocepacia
in vitro lactate production was investigated in order to identify its origin. In
every single CF patient, lactate was detectable (mean ± SD: 3.0±3.1mmol/L,
range 0.2 to 14.1mmol/L). Sputum lactate concentrations correlated negatively with
FEV1 (r = −0.446, p = 0.043). Sputum lactate in the exacerbated patients decreased
from 5.0±3.2mmol/L during exacerbation to 2.3±2.4mmol/L after 2 weeks of i.v.
antibiotic therapy (p = 0.048). Whereas neutrophils produce high amounts of lactate,
bacterial contribution to sputum lactate concentrations is neglectable. Lactate can
be determined using routine methods in sputum samples collected non-invasively
and, thus, may well serve as a marker for treatment of CF lung inﬂammation.
